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ABSTRACT
The combination of the issue of return of individual
genetic results/incidental findings and paediatric
biobanks is not much discussed in ethical literature. The
traditional arguments pro and con return of such findings
focus on principles such as respect for persons,
autonomy and solidarity. Two dimensions have been
distilled from the discussion on return of individual results
in a genetic research context: the respect for
a participant’s autonomy and the duty of the researcher.
Concepts such as autonomy and solidarity do not fit
easily in the discussion when paediatric biobanks are
concerned. Although parents may be allowed to enrol
children in minimal risk genetic research on stored tissue
samples, they should not be given the option to opt out
of receiving important health information. Also, children
have a right to an open future: parents do not have the
right to access any genetic data that a biobank holds on
their children. In this respect, the guidelines on genetic
testing of minors are applicable. With regard to the duty
of the researcher the question of whether researchers
have a more stringent duty to return important health
information when their research subjects are children is
more difficult to answer. A researcher’s primary duty is
to perform useful research, a policy to return individual
results must not hamper this task. The fact that
vulnerable children are concerned, is an additional factor
that should be considered when a policy of returning
results is laid down for a specific collection or research
project.
Paediatric biobanks and longitudinal studies
involving children form an excellent resource to
study the genetic components of conditions that
affect children. However, such collections also raise
ethical questions that are not completely analogous
to those raised by collections containing only adult
material and data.1 As a recent literature review has
shown, the issue of the validity of parental consent
to research on children’s DNA, as well as the
privacy risks associated with the storage of paedi-
atric stored tissue samples and data has been
discussed in some ethical papers already.2 The
protection of children has also been the subject of
a Policy Forum in Science.3e6
Next to the issue of paediatric biobanks, another
topic much discussed in the recent biobank litera-
ture is the return of individual research findings.7
The major questions asked are whether biobanks
should return such individual results to participants
and if so, which results should be returned. Such
research findings may have two forms: there may
be individual findings that are to be expected based
on the study design, and there may be incidental
findings, certain anomalies that were not originally
looked for.8 To date the chance that researchers
may find genetic conditions that they may not be
looking for may seem low. However, with the
advent of new techniques, such findings may
become more frequent. For example, array
comparative genomic hybridization may be used to
study the relation between a certain phenotype and
a copy number variation in a paediatric popula-
tion.9 As the resolution that can be acquired with
this technique can be quite high, it is not
unthinkable that other significant variations are
discovered next to the variations under investiga-
tion.10 Also, with the rise of genome-wide associa-
tion studies studies, it is possible that variants are
found whose significance is not so clear; for
example, they could point to the possibility of late-
onset conditions.11 With the vast increase of
knowledge in the field of genetics it can be expected
that these situations will occur more frequently
and require a thorough investigation.
We admit that the question about the return of
individual results in genetic research is quite
complex. It is nearly impossible to give an answer
fitting all situations. The answer is highly depen-
dent on different variables: the type of genetic
information found, the context (research-only or
research that is still somewhat linked to a diagnos-
tics context) and the capabilities of the researchers.
The type of biobank and modes of recruitment can
also be deciding factors, as the duty to return
results is higher when the recruiter is a general
practitioner (GP) or clinician in frequent contact
with a patient than when the recruiter is
a researcher or research nurse and the contact is one
off. Also, the question is multilayered: what infor-
mation should be returned by the researcher to
a clinical geneticist and/or GP and what informa-
tion should be returned by the latter or the former
to the research participants themselves? There is an
aspect of contingency when incidental findings are
concerned: a researcher working on certain genes
may be unaware of the significance of a variation
that is outside her field. Therefore, not all
researchers may be able to feed all potentially
relevant information back. As we will demonstrate,
we have discovered two dimensions to the ques-
tion, which are often confounded in the literature:
the duty of the researcher to inform versus the
right of the participants to know such information.
These two dimensions, however, cannot be reduced
to one another.
In the next sections we will first describe the
arguments that are usually given pro and con the
return of individual research results. We will give an
overview of the general discussion, which focuses
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on adult participants. Then we will describe our own viewpoint
on the matter. We will end with recommendations for policy
makers. In this paper we will use individual research results both
for the findings that are to be expected in the context of a study
and for incidental findings. We acknowledge that there may be
subtle differences in the ethical dealings with the two kinds of
findings, but for the limited scope of this paper they can be
treated simultaneously; as the net result is very much alike.
OVERVIEW OF THE ARGUMENTS
In the past few years, many articles have discussed the pros and
cons of return of individual genetic results in a research context,
specifically with adult participants in mind. In the theoretical
literature, we basically find three viewpoints here, and some
variants. A first line of thought is that individual research results
should never be returned to research participants. Arguments for
this stance are that genetic results are usually inconclusive, and
as such can cause anxiety.12 Authors also refer to the therapeutic
misconception: returning results could give the impression to
research participants that the research is for their own personal
benefit. Particularly in large biobank contexts there is no need for
researchers to take on the task of clinicians, because these are
primarily focused on the advance of public health.13 Also
returning individual results is considered too resource inten-
sive.14 An example of a biobank with a policy of not returning
individual results is the UK Biobank.15
A second line of thought states that all individual results
should be given to the research participants if they do so want,
as research participants should not be treated as mere means to
(research) ends. Respect for participants means respecting their
autonomy.16 Returning individual results may also ensure better
enrolment.17 The Estonian Gene Bank is an example of
a biobank that recruits through GPs and allows individuals to
access their records and genetic data, but not genealogical
information. It also provides genetic counselling.i The Council
for International Organization of Medical Sciences guideline on
epidemiology specifies that individuals must be informed about
their health status.18
A third line of thought is reflected in the WHO report on
genetic databases19 and in a paper by Bookman et al,20 and states
that individuals have a right to individual research results if
these are of clinical significance, scientific valid and if they
provide a potential benefit to the participants. A National
Institutes of Health-proposed large cohort study is of this
type.17 Related to this is the idea of the ancillary duty of care.21
This concept is based on the idea that when participants signed
up for a study they partly entrust certain aspects of their health
into the researcher ’s hands. So if something is found that can
significantly increase the health of a participant, this informa-
tion should be returned. However, this does not imply that
researchers have an active duty to hunt for findings.
There are several variants of the above positions.22 The much
discussed paper of Ravitsky and Wilfond23 proposes a resulte
evaluation approach based on analytical validity, clinical utility,
context of study, personal meaning to study participants and the
nature of the participanteresearcher relationship. An approach
called ‘tiered disclosure’ by Rothstein24 suggests that partici-
pants could select from options for research disclosure when
they enrol for the study.
From the above arguments, we can distill two dimensions of
the question. These dimensions influence each other but cannot
be reduced to one another. First, there is the question of the right
of the participants to decide for themselves if and what infor-
mation they should receive. Second, there is the duty of the
researcher to return information that has clinical significance
and can be validated. An emphasis on the right to know of the
participant may influence the duty of the researcher, but there
may be valid grounds to relieve the latter of this duty. This does
not automatically imply a disrespect of the former. Moreover,
there may be situations in which the researcher may have the
duty to return certain findings if the wishes of the participants
are unknown, or even contrary to their wishes.
RETURN OF INDIVIDUAL RESULTS IN PAEDIATRIC BIOBANKS
We believe that the question of returning individual results for
paediatric participants does not easily fit in the above models.
We will formulate our own thoughts under the two dimensions
sketched above: ‘participant autonomy ’ and ‘duty of researcher ’.
To conclude, we will formulate some recommendations that can
be used by policy makers.
Participant autonomy
A first dimension in the ethical reflection on the return of
individual results in genetic research on stored tissue samples is
related to the autonomy principle and the right of participants
to decide whether they want to receive certain information
about their health or not. Authors that stress this autonomy
would opt for the second line of thought in our above summary:
individual results should be returned if participants do so wish.
We believe that the situation in the case of paediatric biobanks
enrolling incompetent minors is slightly different, as the persons
making this choice are not the participants themselves.
First, we believe the right not to know does not apply to
parents with regard to information for early-onset treatable or
preventable diseases. In the case of paediatric biobanks, if the
biobank has a policy to return such information, with the
option of opting out, this option should not be made available if
the consent form is filled out by the parents of under-age
participants. We agree that competent adults have the right not
to know their genetic status, even if this can save their own
lives. In this respect we follow the paper by Andorno25 that this
right not to know is based on autonomy and on people’s interest
in not being psychologically harmed by the results of genetic
tests or genetic research. Our situation of parents deciding for
their children is somewhat different, in the sense that the
decision is made for a third person. The autonomy in question is
thus that of the parent and not of the child, and is always
limited by considerations about the best interest of the child. It
is not unthinkable that some parents might opt out of receiving
such information as a result of magical thinking (‘ignorance is
bliss’). Although there are many areas in which parental deci-
sions should not be questioned, this is one area in which others
can take the decision to return information, even against the
parents’ wishes. Take the example of familial adenomatous
polyposis (FAP). Early detection of mutations in the APC gene
can lead to screening for colonic and extracolonic tumours and
can be potentially lifesaving.26 A parent does not have the right
of opting out of receiving such information about his or her
child.
Second, based on the principle of respect for participant’s
autonomy and the right to know, some biobanks may have the
option to provide access to participants to all their individual
genetic information if they do so want. However, this should
not apply when parents have enrolled their children in the
biobank. In the clinical context, literature on genetic screeningi http://www.geenivaramu.ee/index.php?id¼110.
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and testing of minors has amply discussed the negative side-
effects of allowing parents access to non-crucial genetic infor-
mation. On a practical level, knowing that a child carries
a certain gene associated with a condition later in life may cause
anxiety in a family. Parents may start treating their children as if
they already have the condition.27 28 Carrier status may be
interpreted as having an effect on their child’s health. On a more
theoretical level, children should have a right to an open
future,29 to decide on the information they want to know about
themselves when they are ready to do so, and be shielded from
too much curiosity from their parents’ side. We believe, based on
these data, that allowing parents full access to all genetic data of
their children, possibly out of respect for parental autonomy, is
not in the best interest of the children in question and should be
prohibited.
In a research context, the same considerations apply. One
guideline on research on human tissue of the UK Medical
Research Council30 even explicitly specifies that ‘Tests of known
predictive value for adult-onset diseases should not be done for
research purposes on individually identifiable samples from
children’. Even if anonymous epidemiological research on such
diseases may, for practical purposes, in some cases be allowed on
paediatric samples such as DNA from blood spot cards, we agree
that the same restrictions should apply with regard to return of
individual research findings. If postponing the access to such
information does not deprive children of possible preventable
treatment, it should be delayed until later and left to the choice
of the participant when he or she becomes an adult.31 Some may
argue that there can be some benefit in knowing early-onset
unpreventable or untreatable disorders.31 However, these bene-
fits are not completely transparent, and as we are speaking here
of non-sought-for information in a research context, we believe
such information should not be communicated.
In the case of research on stored tissue samples and data,
a complicating issue is the fact that such tissue samples are often
stored for longer periods of time, and that the research can
continue after the child has reached the age of competence. At
this point, the participant should be allowed to make the same
decisions as other ‘adult’ participants. If the biobank gives web
access to participants to their genetic data, this should be given
to participants when they turn 18 years of age.
Duty of researchers
Up till now, our suggestions focused on the right (not) to know
and on participant’s autonomy. However, a difficult question is
still untouched: is a ‘no individual results shall be returned’
policy for adults, like that of the UK Biobank still defensible
when children are concerned? As we have seen before, the
advocates of such a position (our first ‘line of arguments’) refer
to the fact that genetic results are inconclusive and can cause
anxiety, the therapeutic misconception, the duty to solidarity to
participate (and not expect anything back) and the fact that the
administrative burden of a policy of returning results would stall
important research.
The first argument refers to the fact that genetic results are
inconclusive and cause anxiety. However, for well-known early-
onset treatable or preventable conditions this argument does not
hold. Of course communication of such information may never
be only communication of the plain facts, and may thus be
outside of the researcher ’s competence. We observe that the
genetic research children participate in is often of the type of
a longitudinal cohort study, which allows for frequent contact
with researchers and research nurses. Or children who already
have a medical condition are enrolled through their physician or
clinical geneticist. Therefore, the infrastructure for good follow-
up is already there. Moreover, there is a fundamental difference
between adult and paediatric research participants. The latter
have limited autonomy and are as such vulnerable. They have
not enrolled themselves in the research, and as such it is
acknowledged that they are in need of extra protection. In the
literature on clinical trials, there is often the requirement that
research on children should be for the benefit of children.32
Although we admit that research on paediatric tissue samples is
different from clinical trials due to the minimal physical risk
involved, we think that the communication of findings of early-
onset treatable and preventable diseases can be interpreted as
a benefit in this context. In this respect, the ‘therapeutic
misconception’ argument is also flawed. We agree that parents
and children should be aware that research is not done for their
own benefit; we do not believe that this potential misconception
is enough reason not to return important health information
about vulnerable participants.
This relation between vulnerability and benefit requires some
further elaboration. A concept that can be of help here is the
‘duty of care’ of researchers. In this respect, the term ‘ancillary
care’ has been framed. Such care is care that is not required to
make a study scientifically valid. For example, the following up
on a diagnosis found by protocol tests or treating ailments that
are unrelated to the study ’s aim would be ancillary care.33 34 The
return of findings about early-onset treatable or preventable
diseases in genetic studies fits this description. This model is
based on the fact that the relationship between participant and
researcher involves a partial entrustment of the former ’s health
to the latter. Indeed, participants entrust medical information
and samples to researchers, and the informed consent process
transfers rights to use these to researchers. In this respect
participants are vulnerable to researchers. Richardson and
Belsky34 acknowledge a general duty to act compassionately
towards the needy, vulnerable and dependent. However, given
the research context, this duty is limited to specific aspects of
the participant’s health. A researcher is not responsible for all
aspects of the health of participants, only those that arise within
the study. The strength of the ancillary care duty is moreover
influenced by different factors, such as the participants’
vulnerability, the risks and burdens of the study, the depth of the
relationship between the researchers and participants and the
modes of alternative access. Do participants have other means to
obtain the same information?
We think that this ancillary care model is specifically appli-
cable to children in genetic research. First, genetic information is
not typically acquired in ordinary health care. Second, many of
such research, when done on children, involves a close contact
between researchers and under-age participants. Third, children
are recognised as a vulnerable population, which would make
them especially entitled to ancillary care from researchers.
Richardson and Belsky34 link the vulnerability of research
participants to the fact that they transfer certain aspects of their
health to researchers. With children, this is further complicated
by the fact that they often do not make the decision to partic-
ipate themselves. Indeed, vulnerability in children is linked to
their lack of autonomy. As we do not know (with small chil-
dren) what their choice would be, or as their current choice (as
an older child) may not be their ‘definite’ one, children may seem
vulnerable in their choices. Indeed, we should prevent them
from making choices that are too definite and that would close
down other options later on.29 Therefore, the fact that the
participants are children would make the ancillary care duty
higher in the case of paediatric biobanks.
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We think returning results about early-onset treatable and
preventable diseases could also satisfy the requirement that
research should be somehow beneficial to children. True, such
research is potentially beneficial to children in general.
However, the fact that these participants are even more
vulnerable, because they have a limited autonomy, may
suggest that there should also be some limited personal
benefit. Such benefit may be interpreted in many ways, but
we think the opportunity to be informed of potentially severe
conditions suits this purpose better than, for example,
a monetary compensation. Indeed, as is argued by Brock,35
children may even have a higher claim to health care than do
adults. This is again linked to their vulnerability, which also
consists of the fact that they do not understand their own
need, and cannot provide for their own health care, unlike
consenting adult participants. Therefore, he argues, access to
health care is not enough, we must make sure children
actually receive it.35 Although it is true that paediatric
biobanks are not diagnostic tools, we believe these reflections
do enhance the ancillary care duty of researchers to provide
information about early-onset treatable and preventable
diseases, if they accidentally stumble upon it.
The third argument, that of solidarity is also problematical.
The principle of solidarity has been used by some authors to
suggest that participants should participate in biobank
research without expecting anything back.36 37 However, the
principle of solidarity cannot be applied without restrictions
to children.37 Children are exempt from certain duties such as
paying taxes and having a job, although other civilised
behaviour is expected from them. At least researchers have
the right to appeal to children to participate in biobank
research. This does not automatically entail that children
need to participate without expecting any benefit back,
especially if this in the form of found information about
preventable or treatable disorders. Moreover, solidarity has an
additional meaning, referring to the idea that the weakest
and most vulnerable in society should be protected and some
of their burdens should be carried by others. Although it is
true that biobank research is not so invasive or burdensome
that children should be exempted from being solidary in this
respect altogether, they may be compensated by at least
providing them with information.
The fourth argument may make the most sense. In some
context, such as (anonymous) epidemiology on blood spot cards
it may be unfeasible to provide individual results because the
infrastructure is not there. We agree with Affleck,14 that in the
context of pure economics, a policy of not returning results may
be allowed. We might extend this argument even for paediatric
biobanks, especially if the burden for the children is very low and
the contact between researchers and children is minimal, as is
sometimes the case for research on older, archived collections.
Related to this, the duty to return individual results is higher if
a GP or a clinician who is in frequent contact with the patient is
involved in the recruitment of the samples than if the recruit-
ment is done by a researcher or a research nurse and there is
no further contact with donors afterwards. However, deciding
not to return individual results may never be just an easy way
out: if the subjects are incompetent minors, the issue of
returning individual results may require even more consideration
for incompetent minors than when adults are concerned,
because the former are vulnerable research subjects with limited
autonomy. This is especially the case in contexts in which
there is a frequent contact between minors and the research
institute.
CONCLUSIONS AND RECOMMENDATIONS
We have distilled two dimensions from the discussion on return
of individual results in a genetic research context: the respect for
a participant’s autonomy and the duty of the researcher.
Starting from these two dimensions, we have investigated what
is different if the research participants are minors, and have
concluded that the arguments pro or con return of individual
results are somewhat different here. With respect to the first
dimension, we believe that parents should not be allowed to opt
out of receiving information about preventable or treatable
early-onset conditions, but they should also not be given access
to any and all genetic data research may produce. As for the
second dimension, because children have a special status in
research, traditional arguments such as those about therapeutic
misconception or solidarity seem flawed, and the duty to return
results that yield important health benefits is greater than with
adult participants. Still, in projects that require no extra contact
with participants such as epidemiology on blood spot cards, and
that do not have the appropriate infrastructure, logistic
considerations may push the pendulum towards the decision
not to return individual results.
We understand that by using the example of the small
incompetent child we are oversimplifying matters. Considering
an older child or a teenager would have to include a decision
whether he or she can or cannot understand what is at stake.
The issue is even more complex when inheritable diseases are at
stake: the age that people can reproduce is lower than the
generally accepted age of majority. To what extent should the
communication of inheritable, but late-onset diseases corre-
spond to the age of sexual maturity? Also, as new genes are
discovered and new treatments are possible, the situation may
become more complex, and more and more genetic variants may
show up that would warrant communication. For example,
there is increasing evidence that aneurysm has a genetic
component.38 If such evidence becomes conclusive, this would
be a good example that should be communicated, even at an
early date. We also think that guidelines for biobank research on
paediatric stored tissue should tackle the issue of the return of
individual results separately when children are concerned. In
particular we propose the following:
< Researchers should return information to parents and
children about early-onset treatable or preventable diseases,
unless there are compelling reasons not to do so.
< If the biobank has a general ‘tick box’ option to allow the
participant to choose whether to receive information or not,
this tick box should not be available to parents on behalf of
their children.
< All other results should be postponed until the child is
18 years of age. At that point, the return of results policy
should be renegotiated with the participant. This is
preferably systematically done but at least before any
communication about health information is done.
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